OneMedNet Receives High Six-Figure Add-On Order Under Multiyear Agreement Announced September 30

The expansion increases data volume by 150% while preserving potential recurring sublicensing revenue and OneMedNet’s source-data rights.

Rhea-AI Summary

OneMedNet (ONMD) received a high six-figure add-on order under its multiyear data licensing agreement with an AI-enabled precision medicine customer. The order exercises an expansion option in the agreement announced September 30, 2026, increasing data volume by 150%. The customer uses the data to train clinical and diagnostic AI models and build a derivative dataset for sale through its own channel.

The structure retains potential recurring sublicensing revenue on future end-customer licenses of that dataset. OneMedNet retains source-data rights, and end customers may not relicense or resell the underlying data.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointHigh six-figure add-on order expands the multiyear agreement announced September 30, 2026.
• Minor pointData volume increases 150% as the customer exercises its expansion option.
• Minor point. Forward-looking: it has not happened yet and may not happen.Potential recurring sublicensing revenue remains available on future end-customer licenses of the partner-sold derivative dataset.
• Minor pointSource-data rights retained; derivative end customers cannot relicense or resell underlying OneMedNet data.

Negative

• None.

Key Figures

Add-on order: High six-figure Data volume increase: 150%

Add-on order

High six-figure

Order under the multiyear agreement

Data volume increase

150%

Expansion option exercised by the customer

Historical Context

1 past event · Latest: Sep 30

1 event

1. Sep 30

   Multiyear data agreement

   24h Move

   +11.1%

   Seven-figure multiyear license included an expansion option and incremental annual sublicensing revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

real-world data, de-identified, multimodal, longitudinal, +1 more

5 terms

real-world data medical

"AI-driven Real-World Data (RWD)"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

de-identified medical

"license for de-identified, multimodal, longitudinal clinical Real-World Data"

Data labeled as de-identified has had names and other direct personal details removed or masked so individual people cannot be readily recognized; think of it like blurring faces and removing name tags from a photo. For investors, de-identification matters because it reduces legal and privacy risk, can change how valuable or usable the data is for research or product development, and affects regulatory compliance and potential liabilities.

multimodal technical

"de-identified, multimodal, longitudinal clinical Real-World Data"

Multimodal describes an approach, product, or system that uses two or more different types of inputs, methods, or channels — for example combining text, images and audio in a technology product, or blending drugs, devices and therapy in medical care. For investors, multimodal solutions can broaden market reach and competitive differentiation but also add development cost, operational complexity and regulatory hurdles; think of it like a hybrid car that offers more capabilities but requires more parts and oversight.

longitudinal medical

"multimodal, longitudinal clinical Real-World Data"

Longitudinal describes observations or data collected from the same subjects or entities repeatedly over time, tracking how things change rather than a single snapshot. For investors it matters because longitudinal information reveals trends, persistence, and potential cause-and-effect (for example in sales, safety outcomes, or earnings), helping distinguish short-term noise from meaningful long-term shifts—like watching a plant grow rather than looking at a single photo.

sublicensing revenue financial

"potential for recurring sublicensing revenue to OneMedNet"

Revenue a licensee receives from granting a third party permission to use intellectual property, technology, products, or rights that the licensee itself acquired under an original license — i.e., payments for sublicenses. Such payments can take the form of upfront fees, milestones, or ongoing royalties and are governed by the terms of the original license (which may restrict sublicensing or require sharing proceeds with the original licensor); recognition and classification of that revenue follow the applicable contract and accounting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expansion option exercised within weeks as customer increases data volume to support its derivative data offering

MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it has received a high six-figure add-on order under the multiyear agreement announced on September 30, 2026. The order exercises the expansion option included in that agreement, increasing data volume by 150% with the commercially scaled AI-enabled precision medicine customer.

The September 30 agreement established a multiyear license for de-identified, multimodal, longitudinal clinical Real-World Data. The customer is using the data to train AI-enabled clinical and diagnostic models and to build a licensable derivative dataset for sale into its own channel. The new add-on order, received within weeks of the original announcement, reflects the customer’s determination that additional data volume is required to support its derivative data offering.

“Our customers come back for repeat data add-on orders for three reasons: the speed with which we deliver, the quality of our full-fidelity longitudinal data, and the depth of our data, which comes from first-party sources: our healthcare provider partners, not intermediaries or secondary markets,” said Aaron Green, President & CEO of OneMedNet. “We’re seeing that play out here. Within weeks of signing on September 30, our customer exercised its expansion option to support its growing derivative data offering, and we expect the relationship to grow as its solution does.”

OneMedNet sources its data from a live network of more than 2,300 healthcare partner sites, applying de-identification at the source at the scale and standards required to train evolving AI foundation models and to meet life sciences commercial data needs.

Order highlights

• High six-figure add-on order, exercising the expansion option under the multiyear agreement announced September 30, 2026.
• Additional data volume requested within weeks of the original announcement to support the customer’s derivative data offering.
• Structure retains the potential for recurring sublicensing revenue to OneMedNet on future end-customer licenses of the partner-sold derivative dataset.
• OneMedNet retains source-data rights. End customers of the derivative may not relicense or resell the underlying OneMedNet data.

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to statements regarding the benefits and capabilities of our products and the customer agreement, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large is OneMedNet’s add-on order under its September 30 agreement?

The add-on order is high six-figure and increases data volume by 150%. It exercises the expansion option under the multiyear agreement announced September 30, 2026, with an AI-enabled precision medicine customer.

Can OneMedNet earn recurring revenue from the customer’s derivative dataset?

The agreement retains the potential for recurring sublicensing revenue to OneMedNet on future end-customer licenses of the partner-sold derivative dataset. OneMedNet retains source-data rights, and derivative end customers may not relicense or resell the underlying OneMedNet data.